Ubs Group Ag Compass Pathways PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Compass Pathways PLC stock. As of the latest transaction made, Ubs Group Ag holds 63 shares of CMPS stock, worth $538. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 63 -0.0%

Holding current value

$538

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	N/A	-1,133 Reduced 94.73%	63 $0
Q1 2024 May 13, 2024	SELL	N/A	-8,015 Reduced 87.02%	1,196 $10,000
Q4 2023 Feb 09, 2024	SELL	N/A	-5,447 Reduced 37.16%	9,211 $78,000
Q3 2023 Nov 09, 2023	BUY	N/A	12,726 Added 658.7%	14,658 $125,000
Q2 2023 Aug 11, 2023	SELL	$7.79 - $10.69 $33,941 - $46,576	-4,357 Reduced 69.28%	1,932 $16,000
Q1 2023 May 12, 2023	BUY	$7.32 - $10.85 $14,625 - $21,678	1,998 Added 46.56%	6,289 $62,000
Q4 2022 Feb 08, 2023	BUY	$7.84 - $11.68 $24,006 - $35,764	3,062 Added 249.15%	4,291 $34,000
Q3 2022 Nov 10, 2022	BUY	$10.73 - $20.07 $2,500 - $4,676	233 Added 23.39%	1,229 $13,000
Q2 2022 Aug 10, 2022	SELL	$6.76 - $14.18 $9,153 - $19,199	-1,354 Reduced 57.62%	996 $11,000
Q1 2022 May 16, 2022	BUY	$11.13 - $23.04 $5,832 - $12,072	524 Added 28.7%	2,350 $31,000
Q4 2021 Feb 14, 2022	SELL	$21.81 - $48.96 $42,551 - $95,520	-1,951 Reduced 51.65%	1,826 $40,000
Q3 2021 Nov 15, 2021	BUY	$29.03 - $38.62 $26,417 - $35,144	910 Added 31.74%	3,777 $114,000
Q2 2021 Aug 13, 2021	BUY	$32.29 - $39.68 $92,575 - $113,762	2,867 New	2,867 $109,000
Q1 2021 May 12, 2021	SELL	$34.75 - $57.5 $8,513 - $14,087	-245 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$32.0 - $59.2 $7,840 - $14,504	245 New	245 $12,000

Others Institutions Holding CMPS

# of Institutions

151

Shares Held

33.6M

Call Options Held

536K

Put Options Held

582K

View Full List

About COMPASS Pathways plc

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

More about CMPS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account